Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of KEVEYIS and Macrilen.

From 2023 to 2026, Pauls served on the board of Soleno Therapeutics, including as lead independent director from 2024 through its $2.9 billion acquisition by Neurocrine Biosciences. Earlier in his career, he served as chief commercial officer of Insmed Incorporated (Nasdaq: INSM) and held senior roles at Shire Pharmaceuticals, Bristol Myers Squibb, and Johnson & Johnson.

He currently serves on the boards of Pelthos Therapeutics (NYSE American: PTHS) and Atsena Therapeutics.

"We are pleased to add Matt Pauls to our Board as Palvella enters an exciting period of regulatory, commercial and pipeline advancement," said Wes Kaupinen, founder and chief executive officer of Palvella Therapeutics.

Palvella is developing therapies for rare skin diseases and vascular malformations for which no FDA-approved treatments currently exist. Its lead product candidate, QTORIN rapamycin, is under development for conditions including microcystic lymphatic malformations and cutaneous venous malformations. Both QTORIN rapamycin and QTORIN pitavastatin remain investigational and have not received FDA approval.